Making Progress Towards
Uncompromised Protection

Chimerix is developing innovative antiviral medicines for patient populations with weakened immune systems. We also see significant opportunities for expansion into viral diseases that have significant global impact and for which there are currently no effective treatments.

PRODUCT PIPELINE

Program
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Phase
Adenovirus, which causes brief respiratory or gastrointestinal infections in people with healthy immune systems, can lead to life-threatening infections in people who are immunocompromised.4 Chimerix completed the AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic stem cell transplant recipients. View the final data here. The company has initiated the AdAPT (Adenovirus After Pediatric Transplantation) study, a comparative trial of brincidofovir for the treatment of adenovirus in pediatric stem cell transplant recipients. For more information on the AdAPT trial, visit clinicaltrials.gov.
Chimerix is currently developing an intravenous formulation of brincidofovir (CMX001), which may provide the ability to prevent and treat CMV, BK virus and other viral infections.
Noroviruses are the most common cause of acute gastroenteritis worldwide. In immunocompromised adults, norovirus infection can become chronic and persist for weeks to years.8 Chimerix has initiated Phase 1 clinical trials for the treatment of norovirus with CMX521.
Brincidofovir is being developed for smallpox under the FDA’s Animal Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. Results from a study of brincidofovir in a rabbit model of smallpox showed improved survival, even when treatment was initiated during the course of disease. Learn more about the study here. The company is planning a second animal model study in mice.